Healthcare

Amplia Therapeutics Limited (ASX:ATX)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Biotechnology

Market Price : AUD 0.210.015 (7.692%)

(as on 2021-09-26 10:27:23)

Market Cap : AUD 26.212 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.195 0.2 0.21 0.195L 0.21 H 0.16L 0.37 H
Last Trade 0.21
Change% 7.6923
52 W H/L 0.37/0.16
EBITDA -3.873 M
NPAT After Abnormal Items -2.281 M
Equity 10.34 M
ROE% -22.06%
Total Liabilities 539,130
Total Revenue 1.59 M
Cash and Cash Equivalents 1.848 M

Stock Information

Share price 0.21
Market Cap 26.212 M
Price/Gross Cash Flow -17.58
Dividend Yield Excluding Special 0.00%
Ending Shares 107.973 M
52-Week Range 0.16-0.37
P/E ratio 0.000
Sector P/E --
EPS -2.40
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.02
Net Gearing -17.88%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.02
Sales Per Share 0.00
Book Value Per Share 0.10

Announcements

Heading Date/Time
Phase 2 Trial in First-Line Pancreatic Cancer Patients  15/09/2021 9:10AM
Updated Investor Presentation  15/09/2021 8:59AM
Change of Director's Interest Notice - Jane Bell  06/09/2021 10:57AM
Results of Annual General Meeting  27/08/2021 3:00PM
AGM - Chief Executive Officer's Presentatioin  27/08/2021 11:39AM
Annual General Meeting Arrangements  20/08/2021 10:40AM
Quarterly Activities and Cashflow Reports and Presentation  28/07/2021 8:24AM
Shareholder Update and Presentation  26/07/2021 10:35AM
App 4G - Key to Corporate Governance Disclosures  23/07/2021 1:58PM
2021 Corporate Governance Statement  23/07/2021 1:42PM
Annual Report to Shareholders - YE 31 March 2021  23/07/2021 1:40PM
Notice of Annual General Meeting/Proxy Form  23/07/2021 1:39PM
Results from Successful Phase 1 Clinical Trial of AMP945  21/07/2021 8:21AM
Financial Report YE 31 March 2021 - Audited  29/06/2021 3:43PM
Amplia and Garvan Enter Into Collaboration Agreement  28/06/2021 8:32AM
Annual General Meeting to be Held 27 August 2021  25/06/2021 9:33AM
Change of Director's Interest - Dr. Lambert Exercise Options  08/06/2021 9:15AM
Application for quotation of securities - ATX  07/06/2021 5:14PM
Application for quotation of securities - ATX  07/06/2021 4:16PM
AMP945 Improves Survival in Pacnreatic Cancer Model  02/06/2021 8:45AM
Application for Quotation of Shares - Options Exercised  01/06/2021 4:18PM
App 4E - Preliminary Final Report YE 31 March 2021  31/05/2021 10:45AM
Change in substantial holding  11/05/2021 8:20AM
Section 708A Cleansing Notice - Share Placement  10/05/2021 5:15PM
Appendix 2A - Application for Quotation of Shares  10/05/2021 4:56PM
Appendix 3G - Notification of Issue of Securties - Options  10/05/2021 4:53PM
Proposed issue of Securities - ATX  04/05/2021 10:04AM
Amplia Announces $3.8m Share Placement  04/05/2021 9:49AM
Trading Halt  30/04/2021 9:22AM

Similar Companies

Related Articles

About Company

Amplia Therapeutics Limited is based in Melbourne, Australia. It is engaged with the development of FAK (Focal Adhesion Kinase) for the treatment of diseases like cancer and fibrosis. FAK is positioning itself as a significant pick in the cancer immunology and Amplia. Some of the company’s drug candidate include- AMP945 & AMP886.

Corporate Information

company address Level 21, 90 Collins Street, MELBOURNE, VIC, AUSTRALIA, 3000

company phone(02) 8003 3650

company websitehttp://www.ampliatx.com

Dividends

Ex-Dividend Date Franking DPS (AUD) Dividend Yield
30/03/2021 -- 0.000 0.00%
30/03/2020 -- 0.000 0.00%
30/03/2019 -- 0.000 0.00%
30/03/2018 -- 0.000 0.00%
30/03/2017 -- 0.000 0.00%
30/03/2016 -- 0.000 0.00%
30/03/2015 -- 0.000 0.00%
30/03/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 --

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-07-22 2022
Report (Prelim) 2022-05-30 2022
Report (Interim) 2021-11-26 2021

Financials

Breakdown 30/03/2021 30/03/2020 30/03/2019 30/03/2018 30/03/2017
Trading Revenue -- -- -- -- --
Other Revenue 1.59 M 34,227 64,846 642,837 1.831 M
Total Revenue 1.59 M 34,227 64,846 642,837 1.831 M
Interest Income 1,293 3,716 20,284 26,971 61,192
Interest Expenses 0 0 0 0 0
Expenses -3.872 M -2.257 M -1.953 M -4.947 M -8.932 M
EBITDA -2.282 M -2.222 M -1.889 M -4.304 M -7.101 M
Depreciation and Amortization -672 -801 -1,590 -20,161 -36,952
Depreciation -672 -801 -1,590 -20,161 -36,952
Amortisation 0 0 0 0 0
EBIT -2.282 M -2.223 M -1.89 M -4.325 M -7.138 M
Pre Tax Profit -2.281 M -2.219 M -1.87 M -4.298 M -7.076 M
Tax Expense 0 0 0 0 0
Net Profit After Tax -2.281 M -2.219 M -1.87 M -4.298 M -7.076 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 0 0 0 0 0
Reported Net Profit After Abnormal Items -2.281 M -2.219 M -1.87 M -4.298 M -7.076 M
Ending Shares 107.973 M 71.852 M 44.35 M 24.392 M 24.392 M
Weighted Average Shares 94.693 M 52.401 M 42.979 M 24.392 M 22.998 M
EPS After Abnormal Items (cents) -2.41 -4.24 -4.35 -17.62 -30.77
Breakdown 30/03/2021 30/03/2020 30/03/2019 30/03/2018 30/03/2017
Total Current Assets 2.936 M 1.178 M 1.252 M 2.644 M 7.375 M
Total Non Current Assets 7.943 M 7.939 M 7.94 M 0 162,219
Total Assets 10.879 M 9.116 M 9.191 M 2.644 M 7.537 M
Total Current Liabilities 539,130 510,620 526,859 279,422 907,873
Total Non Current Liabilities 0 0 0 0 0
Total Liabilities 539,130 510,620 526,859 279,422 907,873
Net Assets 10.34 M 8.606 M 8.664 M 2.364 M 6.629 M
Breakdown 30/03/2021 30/03/2020 30/03/2019 30/03/2018 30/03/2017
Net Operating Cash -2.916 M -2.088 M -987,348 -3.549 M -6.162 M
Net Invested Cash -5,347 0 -3,188 1,865 -46,527
Net Financing Cash Flows 3.663 M 1.958 M -12,143 -12,911 8.715 M
End Cash Position 1.848 M 1.108 M 1.241 M 2.229 M 5.763 M
Beginning Cash 1.108 M 1.241 M 2.229 M 5.763 M 3.201 M
Exchange Rate Adjustments -1,411 -2,746 14,398 25,683 56,171
Other Cash Adjustments 0 0 0 0 0
Ending Cash 1.848 M 1.108 M 1.241 M 2.229 M 5.763 M

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ) at www.morningstar.com.au/s/fsg.pdf and www.morningstar.com.au/s/fapds.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under license from ASX Operations Pty Ltd ACN 004 523 782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK